Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings outcomes as we speak.
Reported gross sales elevated 5.2% year-over-year to $22.5 billion.
GAAP earnings decreased 37.5% to $2.7 billion whereas EPS fell 34% to $1.11 in comparison with final 12 months. Adjusted EPS was down 9% to $2.42.
For full-year 2024, JNJ expects reported gross sales of $88.4-88.8 billion and adjusted EPS of $9.88-9.98.
(This story can be up to date shortly with an infographic)
Apr 13, 2026, 11:21 AM ETVanguard Russell 3000 Index Fund ETF (VTHR), IWV, IWB, IWR, IWC, IWN, IWO, IWMIVW, IWF,...
Northwest Bancshares Inc. stock reached a new 52-week high, closing at 13.62 USD. This milestone reflects a significant upward trajectory...
BECKY QUICK: Warren, welcome. It is wonderful to see you this morning.WARREN BUFFETT: It is fun to be on.QUICK: You are on...
Managed future strategies are gaining renewed attention as investors look for new sources of returns from the market at a...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
